• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Iperion Life Sciences Becomes Part of Deloitte

Article

Deloitte has announced its acquisition of Iperion Life Sciences Consultancy (Vlijmen, The Netherlands). As of May 1, Iperion is operating as Iperion — a Deloitte business. The business will run as part of Deloitte’s Risk Advisory function. Iperion’s co-founder Frits Stulp will serve as a partner within the Deloitte Risk operation, and his counterpart Karel Bastiaanssen has committed to supporting the integration and growth of Iperion in the coming years. The home base of Iperion will remain in Vlijmen, the Netherlands.

Iperion was founded six years ago with the aim of boosting innovation in life sciences by promoting the structuring and digitizing of regulated data required for the approval and monitoring of medicines.

Speaking for Iperion, Frits Stulp said: “Deloitte and Iperion have been collaborating on innovative digitization projects at pharmaceutical companies for years. The integration with Deloitte is a logical next step to further shape the ambitions and growth strategy of both organizations in this area by, among other things, joining our efforts to implement the data standard ISO IDMP”.

Recent Videos
Related Content